Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Oruka Therapeutics, Inc.NASDAQ: ORKA

Operating Expenses · Q3 FY2026 · quarter ended Sep 2026

Operating expenses growth accelerates

Q3 FY2026 operating expenses of $62.09M rose 82.0% year over year, ahead of the +45.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 24.0% from the prior quarter. Over 3 fiscal years it compounded at +132.3% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +82.0% holds above the trailing-twelve-month pace of +45.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$62.09M+24.0% QoQ
Last fiscal yearDec 2025
$121.97M+38.4% YoY
LTMSep 2026
$182.95M+45.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+82.0%——
1 year+38.4%——
3-year CAGR+132.3%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
121.97M USD
Year-over-year change
+38.4%
4-year CAGR
+58.7%

Operating Expenses vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's LTM Sep 2026 operating expenses of $182.95M is the 6th highest of the 10 companies compared; the peer median is $219.67M.
  • Its year-over-year change of +45.3% is the 5th highest of 10, against a peer median of +23.4%.
  • Over three fiscal years its annual growth of +132.3% compares with a peer median of +56.5%.
ORKA Competitors Peer median
Operating Expenses for ORKA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALMSAlumis Inc. Common StockLTM Jun 2026$465.53M +1.6%+58.0%6292.6%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$265.04M +55.2%+55.0%—
XNCRXencor, Inc.LTM Jun 2026$261.54M +14.7%+83.3%249.1%
ANABAnaptysBio, Inc.LTM Mar 2026$229.74M +420.0%+71.3%98.9%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$219.67M +63.0%+70.8%11537.4%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$182.95M +45.3%+132.3%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$86.87M -40.0%-8.6%1038.2%
ZURAZura Bio LimitedLTM Mar 2026$81.49M +23.4%+40.4%—
ATTOAttovia Therapeutics, Inc.FY2025$67.71M +64.2%—5015.2%
CNTBConnect Biopharma Holdings LimitedFY2025$58.14M +19.9%-21.3%90840.6%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ORKA) $219.67M+23.4%+56.5%5015.2%

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue91K114K111K27K83K
Gross Profit(91K)(114K)(111K)(27K)(83K)
Gross Margin—————
Research & Development13.83M4.46M1.01M75.06M100.64M
Selling, General & Admin5.41M5.26M6.17M13.04M21.33M
Operating Expenses19.24M9.73M7.19M88.1M121.97M
Depreciation & Amortization91K114K111K27K83K
EBITDA(19.23M)(9.81M)(5.23M)(82.23M)(105.35M)
EBITDA Margin—————
Operating Income(19.34M)(9.84M)(7.3M)(88.12M)(122.05M)
Operating Margin—————
Interest Income0675K1.96M5.86M16.63M
Interest Expense0001.47M0
Other Income / Expenses13K(85K)1.96M4.4M16.62M
Income Before Tax(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(19.32M)(9.93M)(5.34M)(83.72M)(105.43M)
Net Margin—————
EPS (Basic)(16.68)(8.27)(4.44)(4.99)(2.31)
EPS (Diluted)(16.68)(8.27)(4.44)(4.99)(2.31)
Weighted Avg Shares13.9M14.41M14.42M16.79M45.61M
Weighted Avg Shares (Diluted)13.9M14.41M14.42M16.79M45.61M

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.